Pre- and postoperative treatment modalities for esophageal squamous cell carcinoma

Anticancer Research

Volumn 32, Issue 11, 2012, Pages 4609-4627

  Thallinger, Christiane M R ^a   Kiesewetter, Barbara ^a   Raderer, Markus ^a   Hejna, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Esophageal squamous cell carcinoma; Perioperative treatment; Review

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; MITOMYCIN; VINBLASTINE; VINDESINE;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; DISEASE FREE SURVIVAL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS SURGERY; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSTOPERATIVE CARE; PREOPERATIVE CARE; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; REVIEW; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW;

CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; HUMANS; NEOADJUVANT THERAPY; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84872671281     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Bystricky B, Okines AF and Cunningham D: Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs 71(5): 541-555, 2011.
2. Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61(4): 212-236, 2011.
3. Glickman JN: Section II: Pathology and pathologic staging of esophageal cancer. Semin Thorac Cardiovasc Surg 15(2): 167-179, 2003.
4. Siewert JR and Ott K: Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol 17(1): 38-44, 2007.
5. Atkins BZ, Shah AS, Hutcheson KA, Mangum JH, Pappas TN, Harpole DH Jr. and D'Amico TA: Reducing hospital morbidity and mortality following esophagectomy. Ann Thorac Surg 78: 1170-1176, 2004.
6. Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H and Fink U: Histologic tumor type is an independent prognostic parameter in esophageal cancer: Lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg 234(3): 360-367, 2001.
7. Akiyama H, Tsurumaru M, Udagawa H and Kajiyama Y: Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 220(3): 364-372, 1994.
8. Adolf J, Frehner W, Sterk P and Pfeiffer A: Thoracoscopically assisted en bloc esophagectomy. Chirurg 80(9): 848-853, 2009.
9. Mariette C, Piessen G and Triboulet JP: Therapeutic strategies in oesophageal carcinoma: Role of surgery and other modalities. Lancet Oncol 8(6): 545-553, 2007.
10. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
11. Brucher BL, Becker K, Lordick F, Fink U, Sarbia M, Stein H, Busch R, Zimmermann F, Molls M, Höfler H and Siewert JR: The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer 106: 2119-2127, 2006.
12. Rebollo Aguirre AC, Ramos-Font C, Villegas Portero R, Cook GJ, Llamas Elvira JM and Tabares AR: Fluorodeoxyglucose positron emission tomography for the evaluation of neoadjuvant therapy response in esophageal cancer: Systematic review of the literature. Ann Surg 250: 247-254, 2009.
13. Fink U, Stein HJ, Bochtler H, Roder JD, Wilke HJ and Siewert JR: Neoadjuvant therapy for squamous cell esophageal carcinoma. Ann Oncol 5: 17-26, 1994.
14. Roth JA, Pass HI, Flanagan MM, Graeber GM, Rosenberg JC and Steinberg S: Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg 96(2): 242-248, 1988.
15. Nygaard K, Hagen S, Hansen HS, Hatlevoll R, Hultborn R, Jakobsen A, Mäntyla M, Modig H, Munck-Wikland E and Rosengren B: Preoperative radiotherapy prolongs survival in operable esophageal carcinoma: A randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 16(6): 1104-1109, 1992.
16. Schlag PM: Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. The Chirurgische Arbeitsgemeinschaft Fuer Onkologie der Deutschen Gesellschaft Fuer Chirurgie Study Group. Arch Surg 127(12): 1446-1450, 1992.
17. Ancona E, Ruol A, Castoro C, Chiarion-Sileni V, Merigliano S, Santi S, Bonavina L and Peracchia A: First-line chemotherapy improves the resection rate and long-term survival of locally advanced (T4, any N, M0) squamous cell carcinoma of the thoracic esophagus: Final report on 163 consecutive patients with 5-year follow-up. Ann Surg 226: 714-723, 1997.
18. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD and Roth JA: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339(27): 1979-1984, 1998.
19. Ancona E, Ruol A, Castoro C, Chiarion-Sileni V, Merigliano S, Santi S, Bonavina L and Peracchia A: Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long-term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 91: 2165-2174, 2001.
20. Medical Research Council Oesophageal Cancer Working Group: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet 359: 1727-1733, 2002.
21. Allum WH, Stenning SP, Bancewicz J, Clark PI and Langley RE: Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 27(30): 5062-5067, 2009.
22. Maipang T, Vasinanukorn P, Petpichetchian C, Chamroonkul S, Geater A, Chansawwaang S, Kuapanich R, Panjapiyakul C, Watanaarepornchai S and Punperk S: Induction chemotherapy in the treatment of patients with carcinoma of the esophagus. J Surg Oncol 56(3): 191-197, 1994.
23. Law S, Fok M, Chow S, Chu KM and Wong J: Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: A prospective randomized trial. J Thorac Cardiovasc Surg 114(2): 210-217, 1997.
24. Baba M, Natsugoe S, Shimada M, Nakano S, Kusano C, Fukumoto T, Aikou T and Akazawa K: Prospective evaluation of preoperative chemotherapy in resectable squamous cell carcinoma of the thoracic esophagus. Dis Esophagus 13(2): 136-141, 2000.
25. Matsuyama J, Doki Y, Yasuda T, Miyata H, Fujiwara Y, Takiguchi S, Yamasaki M, Makari Y, Matsuura N, Mano M and Monden M: The effect of neoadjuvant chemotherapy on lymph node micrometastases in squamous cell carcinomas of the thoracic esophagus. Surgery 141: 570-580, 2007.
26. Cao XF, He XT, Ji L, Xiao J and Lv J: Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma. Dis Esophagus 22(6): 477-481, 2009.
27. Bhansali MS, Vaidya JS, Bhatt RG, Patil PK, Badwe RA, Desai PB: Chemotherapy for carcinoma of the esophagus: A comparison of evidence from meta-analyses of randomized trials and of historical control studies. Ann Oncol 7(4): 355-359, 1996.
28. Urschel JD, Vasan H and Blewett CJ: A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg 183: 274-279 2002.
29. Kaklamanos IG, Walker GR, Ferry K, Franceschi D and Livingstone AS: Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: A meta-analysis of randomized clinical trials. Ann Surg Oncol 10(7): 754-761, 2003.
30. Malthaner RA, Collin S and Fenlon D: Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev 19;3 : CD001556, 2006.
31. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J; Australasian Gastro-Intestinal Trials Group: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet Oncol 8(3): 226-234, 2007.
32. Graham AJ, Shrive FM, Ghali WA, Manns BJ, Grondin SC, Finley RJ and Clifton J: Defining the optimal treatment of locally advanced esophageal cancer: A systematic review and decision analysis. Ann Thorac Surg 83 : 1257-1264, 2007.
33. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A and Gebski V; Australasian Gastro-Intestinal Trials Group: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12(7): 681-692, 2011.
34. Kranzfelder M, Schuster T, Geinitz H, Friess H and Büchler P: Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. Br J Surg 98(6): 768-783, 2011.
35. Launois B, Delarue D, Campion JP and Kerbaol M: Preoperative radiotherapy for carcinoma of the esophagus. Surg Gynecol Obstet 153(5): 690-692, 1981.
36. Gignoux M, Roussel A, Paillot B, Gillet M, Schlag P, Favre JP, Dalesio O, Buyse M and Duez N: The value of preoperative radiotherapy in esophageal cancer: results of a study of the E.O.R.T.C. World J Surg 11(4): 426-432, 1987.
37. Arnott SJ, Duncan W, Kerr GR, Walbaum PR, Cameron E, Jack WJ and Mackillop WJ: Low dose preoperative radiotherapy for carcinoma of the oesophagus: Results of a randomized clinical trial. Radiother Oncol 24(2) : 108-113, 1992.
38. Wang M, Gu XZ, Yin WB, Huang GJ, Wang LJ and Zhang DW: Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of esophageal carcinoma: Report on 206 patients. Int J Radiat Oncol Biol Phys 16(2): b325-327, 1989.
39. Arnott SJ, Duncan W, Gignoux M, Hansen HS, Launois B, Nygaard K, Parmar MK, Rousell A, Spilopoulos G, Stewart G, Tierney JF, Wang M, Rhugang Z; Oeosphageal Cancer Collaborative Group: Preoperative radiotherapy for esophageal carcinoma, Cochrane Database Syst Rev 4: CD001799, 2005.
40. Kelsen DP, Minsky B, Smith M, Beitler J, Niedzwiecki D, Chapman D, Bains M, Burt M, Heelan R and Hilaris B: Preoperative therapy for esophageal cancer: A randomized comparison of chemotherapy versus radiation therapy. J Clin Oncol 8(8): 1352-1361,1990.
41. Fok M, McShane J, Law S, Choy D, Cheng SW and Wong J: Prospective randomized study of radiotherapy and surgery in the treatment of oesophageal carcinoma. Asian J Surg 17: 223-229, 1994.
42. Le Prise E, Etienne PL, Meunier B, Maddern G, Ben Hassel M, Gedouin D, Boutin D, Campion JP and Launois B: A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 73(7): 1779-1784, 1994.
43. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier JC, Pavy JJ, Mercier M and Sahmoud T: Chemoradiotherapy followed by surgery compared with surgery alone in squamous cell cancer of the esophagus. N Engl J Med 337: 161-167, 1997.
44. Heise JW, Heep H, Frieling T, Sarbia M, Hartmann KA and Röher HD: Expense and benefit of neoadjuvant treatment in squamous cell carcinoma of the esophagus. BMC Cancer 1: 20-25, 2001.
45. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A and Strawderman M: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19: 305-313, 2001.
46. Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Denham JW; Trans-Tasman Radiation Oncology Group; Australasian Gastro-Intestinal Trials Group: Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial. Lancet Oncol 6: 659-668, 2005.
47. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D and Mayer R: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26: 1086-1092, 2008.
48. Lee JL, Park SI, Kim SB, Jung HY, Lee GH, Kim JH, Song HY, Cho KJ, Kim WK, Lee JS, Kim SH and Min YI: A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 15: 947-954, 2004.
49. Apinop C, Puttisak P and Preecha N: A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology 41(4): 391-393, 1994.
50. Natsugoe S, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, Yokomakura N, Ishigami S, Owaki T and Aikou T: Randomized controlled study on preoperative chemoradiotherapy followed by surgery versus surgery alone for esophageal squamous cell cancer in a single institution. Dis Esophagus 19(6): 468-472, 2006.
51. Lv J, Cao XF, Zhu B, Ji L, Tao L and Wang DD: Long-term efficacy of perioperative chemoradiotherapy on esophageal squamous cell carcinoma. World J Gastroenterol 16(13): 1649-1654, 2010.
52. Ruol A, Rizzetto C, Castoro C, Cagol M, Alfieri R, Zanchettin G, Cavallin F, Michieletto S, Da Dalt G, Sileni VC, Corti L, Mantoan S, Zaninotto G and Ancona E: Interval between neoadjuvant chemoradiotherapy and surgery for squamous cell carcinoma of the thoracic esophagus: Does delayed surgery have an impact on outcome? Ann Surg 252(5): 788-796, 2010.
53. Urschel JD and Vasan H: A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 185(6): 538-543, 2003.
54. Fiorica F, Di Bona D, Schepis F, Licata A, Shahied L, Venturi A, Falchi AM, Craxì A and Cammà C: Preoperative chemoradiotherapy for oesophageal cancer: A systematic review and meta-analysis. Gut 53(7) : 925-930, 2004.
55. Malthaner RA, Wong RK, Rumble RB and Zuraw L: Neoadjuvant or adjuvant therapy for resectable esophageal cancer: A systematic review and meta-analysis. BMC Med 2: 35-44, 2004.
56. Stuschke M and Sarbia M: Neoadjuvante Radiochemotherapie und Responseprädiktion. Der Onkologe 10(11): 1179-1190, 2004.
57. Greer SE, Goodney PP, Sutton JE and Birkmeyer JD: Neoadjuvant chemoradiotherapy for esophageal carcinoma: A meta-analysis. Surgery 137(2) : 172-177, 2005.
58. Jin HL, Zhu H, Ling TS, Zhang HJ and Shi RH: Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: A meta-analysis. World J Gastroenterol 15 (47) : 5983-5991, 2009.
59. Wijnhoven BP, van Lanschot JJ, Tilanus HW, Steyerberg EW and van der Gaast A: Neoadjuvant chemoradiotherapy for esophageal cancer: A review of meta-analyses. World J Surg 33(12): 2606-2614, 2009.
60. Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C and Wilke H: Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23: 2310-2317, 2005.
61. Bedenne L, Michel P, Bouché O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F and Binquet C: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25: 1160-1168, 2007.
62. Hsu FM, Lin CC, Lee JM, Chang YL, Hsu CH, Tsai YC, Lee YC and Cheng JC: Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: Results of a retrospective non-randomized study. J Surg Oncol 98 : 34-41, 2008.
63. Pouliquen X, Levard H, Hay JM, McGee K, Fingerhut A and Langlois-Zantin O: 5-Fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. French Associations for Surgical Research. Ann Surg 223(2): 127-133, 1996.
64. Ando N, Iizuka T, Kakegawa T, Isono K, Watanabe H, Ide H, Tanaka O, Shinoda M, Takiyama W, Arimori M, Ishida K and Tsugane S: A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: The Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg 114(2): 205-209, 1997.
65. Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, Takiyama W, Watanabe H, Isono K, Aoyama N, Makuuchi H, Tanaka O, Yamana H, Ikeuchi S, Kabuto T, Nagai K, Shimada Y, Kinjo Y, Fukuda H; Japan Clinical Oncology Group: Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: A Japan Clinical Oncology Group Study - JCOG9204. J Clin Oncol 21(24): 4592-4596, 2003.
66. Lee J, Lee KE, Im YH, Kang WK, Park K, Kim K and Shim YM: Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma. Ann Thorac Surg 80(4): 1170-1175, 2005.
67. Zhang J, Chen HQ, Zhang YW and Xiang JQ: Adjuvant chemotherapy in oesophageal cancer: A meta-analysis and experience from the Shanghai Cancer Hospital. J Int Med Res 36(5): 875-882, 2008.
68. Kunath U and Fischer P: Radical nature and life expectancy in the surgical treatment of esophageal and cardial carcinoma. Dtsch Med Wochenschr 109 (12): 450-453, 1984.
69. Ténière P, Hay JM, Fingerhut A and Fagniez PL: Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research. Surg Gynecol Obstet 173(2): 123-130, 1991.
70. Zieren HU, Müller JM, Jacobi CA, Pichlmaier H, Müller RP and Staar S: Adjuvant postoperative radiation therapy after curative resection of squamous cell carcinoma of the thoracic esophagus: A prospective randomized study. World J Surg 19(3): 444-449, 1995.
71. Fok M, Sham JS, Choy D, Cheng SW and Wong J: Postoperative radiotherapy for carcinoma of the esophagus: A prospective, randomized controlled study. Surgery 113(2) : 138-147, 1993.
72. Xiao ZF, Yang ZY, Liang J, Miao YJ, Wang M, Yin WB, Gu XZ, Zhang DC, Zhang RG and Wang LJ: Value of radiotherapy after radical surgery for esophageal carcinoma: A report of 495 patients. Ann Thorac Surg 75(2): 331-336, 2003.
73. Japanese Esophageal Oncology Group: A comparison of chemotherapy and radiotherapy as adjuvant treatment to surgery for esophageal carcinoma. Japanese Esophageal Oncology Group. Chest 104(1): 203-207, 1993.
74. van Heijl M, van Lanschot JJ, Koppert LB, van Berge Henegouwen MI, Muller K, Steyerberg EW, van Dekken H, Wijnhoven BP, Tilanus HW, Richel DJ, Busch OR, Bartelsman JF, Koning CC, Offerhaus GJ and van der Gaast A: Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS). BMC Surg 8 : 21-26, 2008.
75. Pultrum BB, Honing J, Smit JK, van Dullemen HM, van Dam GM, Groen H, Hollema H and Plukker JT: A critical appraisal of circumferential resection margins in esophageal carcinoma. Ann Surg Oncol 17(3): 812-820, 2010.
76. Ancona E, Cagol M, Epifani M, Cavallin F, Zaninotto G, Castoro C, Alfieri R and Ruol A: Surgical complications do not affect long-term survival after esophagectomy for carcinoma of the thoracic esophagus and cardia. J Am Coll Surg 203: 661-669, 2006.
77. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D and Stroup DF: Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354(9193): 1896-1900, 1999.
78. Tabernero J, Macarulla T, Ramos FJ and Baselga J: Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol 16(11) : 1740-1748, 2005.
79. Tew WP, Kelsen DP and Ilson DH: Targeted therapies for esophageal cancer. Oncologist 10(8): 590-601, 2005.
80. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742): 687-697, 2010.
81. Schoppmann SF, Jesch B, Friedrich J, Wrba F, Schultheis A, Pluschnig U, Maresch J, Zacherl J, Hejna M and Birner P: Expression of HER2 in carcinomas of the esophagus. Am J Surg Pathol 34(12): 1868-1873, 2010.
82. Schoppmann SF, Jesch B, Zacherl J, Wrba F, Hejna M, Maresch J, Langer FB, Riegler MF, Pluschnig U and Birner P: HER2 status in primary oesophageal cancer, lymph nodes and distant metastases. Br J Surg 98(10): 1408-1413, 2011.
83. ClinicalTrail.gov: NCT00525200: p53-Adjusted Neoadjuvant Chemotherapy for Potentially Resectable Esophageal Cancer (pANCHO). Bethesda, MD, US National Institutes of Health, 2011.
84. ClinicalTrail.gov: NCT00002897: Surgery with or without Chemotherapy in Treating Patients with Stage II or Stage III Cancer of the Esophagus. Bethesda, MD, US National Institutes of Health, 2011.
85. ClinicalTrail.gov: NCT01404156: Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiation in Patients with Surgically Resectable Esophageal Cancer: A Pilot Randomized Study. Bethesda, MD, US National Institutes of Health, 2011.
86. ClinicalTrail.gov: NCT00559351: Possibilities for Improvement of an Outcome of the Treatment in Squamous Cell Carcinoma of the Thoracic Esophagus - A Multicenter Randomized Clinical Phase III Trial. Bethesda, MD, US National Institutes of Health, 2011.
87. ClinicalTrail.gov: NCT00193141: Paclitaxel, Carboplatin, Infusional 5-Fluorouracil, and Radiation Therapy with or without Surgical Resection in Locally Advanced Esophageal Cancer. Bethesda, MD, US National Institutes of Health, 2011.
88. ClinicalTrail.gov: NCT00190554: A Randomized Controlled Trial of Chemotherapy with 5-FU and Cisplatin Before and After Surgery for Stage II, III Squamous Cell Carcinoma of the Thoracic Esophagus: JCOG9907. Bethesda, MD, US National Institutes of Health, 2011.
89. ClinicalTrail.gov: NCT00907543: Prospective Randomized Phase III Trial Comparing Preoperative Chemoradiation Therapy (Cisplatin, 5-FU and Radiotherapy Followed by Surgery) to Surgery Followed by Postoperative Chemoradiation (Cisplatin, Epirubicin, 5-FU, Radiotherapy) for Esophageal Cancer. Bethesda, MD, US National Institutes of Health, 2011.
90. ClinicalTrail.gov: NCT00047112: Randomized Study of Pre-Operative Radio-Chemotherapy versus Surgery Alone in Thoracic Esophageal Cancer Deemed to be Resectable. Bethesda, MD, US National Institutes of Health, 2011.
91. ClinicalTrail.gov: NCT01216527: A Phase III, Multicenter Randomized Controlled Study of Neo-adjuvant Chemoradiotherapy Followed by Surgery versus Surgery for Locally Advanced Squamous Cell Esophageal Carcinoma. Bethesda, MD, US National Institutes of Health, 2011.
92. ClinicalTrail.gov: NCT00003118: A Prospective Randomized Phase III Trial Comparing Trimodality Therapy (Cisplatin, 5-FU, Radiotherapy, and Surgery) to Surgery Alone for Esophageal Cancer. Bethesda, MD, US National Institutes of Health, 2011.
93. ClinicalTrail.gov: NCT01107639: Multimodal Therapy with and without Cetuximab in Patients With Locally Advanced Esophageal Carcinoma - An Open-Label Phase III Trial. Bethesda, MD, US National Institutes of Health, 2011.
94. ClinicalTrail.gov: NCT00416858: Radiation Therapy and Combination Chemotherapy with or without Surgery in Treating Patients with Locally Advanced Esophageal Cancer that Can Be Removed By Surgery. Bethesda, MD, US National Institutes of Health, 2011.